The registration of risdiplam (Evrysdi) film-coated tablets in the French Official Journal has just been published.
- This new formulation will be available in pharmacies from 9 June 2026.
- It is indicated for patients with type I, II or III spinal muscular atrophy (SMA), or those with 1 to 4 copies of the SMN2 gene, aged over 2 years, weighing at least 20 kg and able to swallow without a feeding tube.
- It is a bioequivalent alternative to the currently available oral solution.
- And it can be stored at room temperature, unlike the oral solution, which must be kept in the fridge, or exceptionally at room temperature for a maximum of 5 days.
